Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?

Cardiovascular Research

Volumn 52, Issue 2, 2001, Pages 199-207

  Rizos, Evangelos ^a   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cerebrovascular disorders; Cholesterol; Epidemiology; Lipoproteins; Statins

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; BETA CAROTENE; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SMOKING; STROKE; THROMBOCYTE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; BEZAFIBRATE; BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; TRIGLYCERIDES;

EID: 0034782713     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00383-2     Document Type: Article

References (80)

1. Lipids and stroke: Neglect of a useful preventive measure?
2. Lp(a) and stroke
3. Risk factors for ischaemic heart disease and stroke mortality in young and old hypertensive patients
4. Is cholesterol a risk factor for stroke? Yes
5. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
6. Prevention of cardiovascular events and death with pravaststin in patients with coronary heart disease and a broad range of initial cholesterol levels
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Pravastatin therapy and the risk of stroke
9. HDL-cholesterol, total cholesterol and the risk of stroke in middle-aged British men
10. High-density lipoprotein cholesterol and risk of ischaemic stroke mortality
11. Different risk factors for different stroke subtypes
12. Risk factors for ishaemic stroke
13. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease: The Copenhagen city heart study
14. Body height, cardiovascular risk factors and risk of stroke in middle-aged men and women
15. Risk factors for death from different types of stroke
16. Precursors of extracranial carotid atherosclerosis in the Framingham study
17. Cholesterol, diastolic blood pressure and stroke: 13,000 Strokes in 45,0000 people in 45 prospective cohorts
18. An overview of trials of cholesterol lowering and risk of stroke
19. Other risk factors for stroke. Serum risk factors for stroke
20. Prospective study of markers of haemostatic function with risk of ischaemic stroke
21. Prospective associations of fasting insulin, body fat distribution and diabetes with risk of ischaemic stroke
22. Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke
23. Risk factors and their management for stroke prevention
24. Efficacy of 3 HMG CoA reductase inhibitors for prevention of stroke
25. Stroke statins and cholesterol. A meta-analysis of randomised, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
26. Reductase inhibitor monotherapy and stroke prevention
27. Cholesterol lowering with statin drugs, risk of stroke and total mortality
28. Effect of HMG-CoA reductase inhibitors on stroke: A meta-analysis of randomised, controlled trials
29. Cholesterol reduction and stroke occurrence: An overview of randomized clinical trials
30. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
31. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial
32. Secondary prevention and referral of elderly patients to a cardiovascular lipid service
33. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
34. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
35. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
36. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease
37. Lipoproteins, cardiovascular disease and death: The Framingham study
38. Association of transient ischaemic attack/stroke symptoms assessed by standardized questionnaire and algorithm with cerebrovascular risk factors and carotid artery wall thickness. The ARIC study 1987-89
39. Fibrinogen as a risk factor for coronary heart disease
40. Coagulation and fibrinolytic factors as predictors of cardiovascular disease
41. Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by TIA
42. Relation of laboratory and clinical variables to the grade of carotid atherosclerosis
43. Lowering fibrinogen levels: Clinical update
44. Treatment of dyslipidaemias in patients with established vascular disease: A review of the fibrates
45. Bezafibrate: Treating hyperlipidaemias as well as other cardiovascular risk factors
46. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate or lifestyle advice
47. Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
48. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type I I diabetics: A pilot study
49. Platelets and lipid lowering interventions
50. Antiplatelet agents and the prevention of stroke
51. Platelets and lipoprotein (a): A brief review of their role in the pathogenesis of atherothrombosis
52. Lipoprotein (a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease
53. Lipoprotein(a) as a correlate of stroke and TIA prevalence in a biracial cohort: The ARIC study
54. Statins and fibrinogen
55. Smoking, diabetes and hyperlipidaemia
56. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: The 22-year follow up results of the Helsinki Policemen Study
57. Treating dyslipidaemia in non-insulin dependent diabetes mellitus (NIDDM) - A special reference to statins
58. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analysis in the Scandinavian simvastatin survival study
59. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin
60. The effect of short term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: A pilot study
61. A prospective study of plasma homocysteine and risk of ischemic stroke
62. Risk stratification in hypertension: New insights from the Framingham study
63. Lp(a) lipoprotein in cardiovascular disease
64. Primary and subsequent coronary risk appraisal new results from the Framingham study
65. Cardiovascular disease risk profiles
66. Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia
67. The effect of atorvastatin on serum lipids, lipoprotein (a) and plasma fibrinogen levels in primary dyslipidaemia - A pilot study involving serial sampling
68. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia
69. Asymptomatic carotid atherosclerosis study cost/benefit analysis
70. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis
71. Pravastatin for the prevention of stroke
72. Carotid wall thickness is predictive of incident clinical stroke: The ARIC study
73. Associations between carotid atherosclerosis and high factor VIII activity, dyslipidemia and hypertension
74. The epidemiology of low levels of high density lipoprotein cholesterol in patients with and without coronary artery disease
75. The epidemiology of peripheral arterial disease: Importance of identifying the population at risk
76. C-reactive protein as a cardiovascular risk factor
77. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
78. Smoking diminishes the beneficial effect of statins
79. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of efficacy and safety
80. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study